Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmi L Lutsep

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Current Drug Targets. CNS and Neurological Disorders|April 29, 2005
Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic strokeHelmi L Lutsep
Current Neurology and Neuroscience Reports|June 26, 2004
The era of the device in ischemic strokeHelmi L Lutsep
The American Journal of Medicine|April 1, 2009
Recent clinical trials of antiplatelet therapy in secondary stroke prevention: expectations and results for application in primary care settingsHelmi L Lutsep
Current Opinion in Neurology|January 22, 2009
Symptomatic intracranial stenosis: best medical treatment vs. intracranial stentingHelmi L Lutsep
Expert Review of Medical Devices|May 3, 2008
Mechanical endovascular acute stroke treatment: here to stayHelmi L Lutsep
Medscape Journal of Medicine|April 3, 2008
Stroke treatment and prevention are not the same in men and womenHelmi L Lutsep
The American Journal of Medicine|June 6, 2006
MATCH results: implications for the internistHelmi L Lutsep
Expert Review of Neurotherapeutics|July 13, 2006
Thrombolytic and newer mechanical device treatment for acute ischemic strokeHelmi L Lutsep
Expert Review of Neurotherapeutics|August 14, 2013
Medical and lifestyle interventions, not procedures, should be the primary focus in stroke preventionHelmi L Lutsep
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Repinotan BayerHelmi L Lutsep
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Current Drug Targets. CNS and Neurological Disorders|April 29, 2005
Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic strokeHelmi L Lutsep
Current Neurology and Neuroscience Reports|June 26, 2004
The era of the device in ischemic strokeHelmi L Lutsep
The American Journal of Medicine|April 1, 2009
Recent clinical trials of antiplatelet therapy in secondary stroke prevention: expectations and results for application in primary care settingsHelmi L Lutsep
Current Opinion in Neurology|January 22, 2009
Symptomatic intracranial stenosis: best medical treatment vs. intracranial stentingHelmi L Lutsep
Expert Review of Medical Devices|May 3, 2008
Mechanical endovascular acute stroke treatment: here to stayHelmi L Lutsep
Medscape Journal of Medicine|April 3, 2008
Stroke treatment and prevention are not the same in men and womenHelmi L Lutsep
The American Journal of Medicine|June 6, 2006
MATCH results: implications for the internistHelmi L Lutsep
Expert Review of Neurotherapeutics|July 13, 2006
Thrombolytic and newer mechanical device treatment for acute ischemic strokeHelmi L Lutsep
Expert Review of Neurotherapeutics|August 14, 2013
Medical and lifestyle interventions, not procedures, should be the primary focus in stroke preventionHelmi L Lutsep
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Repinotan BayerHelmi L Lutsep
Pageof 7